CRISPR Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Products (Design Tools, Plasmid And Vector, Cas9 And G-RNA, Delivery System Products), By Applications (Genome Editing, Genetic Engineering, GMO And Crops, Human Stem Cells, Others), And By Geography - Forecasts From 2021 To 2026

Published:  Jul 2021 Report Code: KSI061610963 Pages: 112

The Global CRISPR market is evaluated at US$0.979 billion for the year 2019 and is estimated to grow at a CAGR of 35.96% to reach the market size of US$8.406 billion by the year 2026.

The global CRISPR market is a growing industry with major investments from developed countries. The global genome editing market is witnessing a high growth rate after the discovery of a cutting-edge tool- “CRISPR”, a shorthand for “Clustered Regularly Interspaced Short Palindromic Repeats”. CRISPR-based tools are increasingly being adopted by enterprises globally for new developments in fields like genome editing, genetic engineering, biotechnology, pharmaceutical, and agriculture.

The growing need for drug research, the risk of congenital abnormalities, and late pregnancies resulting in birth problems are key factors driving the CRISPR market forward. The escalating geriatric population, Changes in lifestyles, and investment in cutting-edge research technologies are also augmenting the market size. Genetic illnesses are becoming more common, genetic diseases are becoming more prevalent, and people are becoming more aware of gene therapies leading to further development in the market.

Wide possible applications to drive the market growth.

CRISPR technology is widely utilized for a variety of applications. Genome editing, also known as genetic engineering, is a technique for altering an organism's genome by using molecular machinery and designed nucleases to make deletions, insertions, or substitutions in the DNA of a live creature. A gene library is a collection of cloned deoxyribonucleic acid (DNA) fragments that contain information on the functionality of a gene. CRISPR plasmids are widely utilized for gene disruption and homologous gene direct repair.

Pairwise, a CRISPR-focused food business, received USDA authorization in August 2020 for its gene-edited form of Brassica juncea, also known as mustard greens. Pairwise received word from the USDA that their innovative take on a leafy green that hasn't been on many menus owing to a strong odor and unpleasant taste has been authorized to continue ahead. Pairwise wants to produce a healthful and tasty alternative to kale and Brussels sprouts by using CRISPR technology to design modifications.

PerkinElmer and Qiagen are the recent medtechs to enter the fast-developing CRISPR industry, with technology meant to help gene editing to cure cancer, hemophilia, sickle cell anemia, and other illnesses. Qiagen has introduced new CRISPR products to help researchers better understand the gene-editing effect of their work, while PerkinElmer has acquired SIRION Biotech, a German viral vector gene delivery business, to expand its CRISPR gene editing toolkit in June 2021.

A rapid increase in genetic disorders to expand market demand.

The increase in genetic disorders is also facilitating the market demand. According to the Global Alliance for Genomics and Health (GA4GH), over 60 million individuals will have had their genome sequenced in a hospital setting by 2025, yet mechanisms for handling the data generated by genome sequencing are still in their infancy. As reported by US National Center for Biotechnology Information, even though genetic illnesses are individually rare, they constitute around 80% of rare disorders, which number in the thousands. The sheer quantity of uncommon illnesses implies that one out of every seventeen people is affected by it.

Capsida Biotherapeutics, a US-based startup, was formed in 2019 to employ gene therapy to treat severe illnesses. The firm just disclosed a significant development that might hasten its ambitions. The firm announced a collaboration with CRISPR Therapeutics, a pioneer in gene-based medicine, in June 2021 to co-develop therapies for two uncommon diseases with no known cures: Lou Gehrig's disease or amyotrophic lateral sclerosis (ALS) and Friedreich's ataxia.

Escalating Research & Development to provide opportunities to the market players.

A lot of research and development happening in the market is anticipated to boost the opportunities through the inclining market trends. As reported by US National Cancer Institute, Since the discovery that mutations in DNA cause cancer, scientists have been looking for a simple approach to reverse such changes by altering DNA. Several techniques of gene editing have been developed over the years, but none have truly satisfied the criteria for a rapid, simple, and low-cost technology. Cancer researchers leaped at the possibility to utilise CRISPR as soon as it hit the shelves and freezers of labs throughout the world. CRISPR is now being tested on cancer patients rather than in lab dishes. Researchers tested a cancer treatment involving immune cells that were CRISPR-edited to better hunt down and attack cancer in a small study.

Insufficient awareness and the potential misuse to restrain the market growth.

The primary obstacles impeding the CRISPR market's growth are insufficient awareness and the potential misuse of CRISPR gene editing technologies. This technology faces a major challenge in developing nations such as those in the Asian and African regions, where potential consumers are ignorant of its extensive usage in several key research initiatives.

Geographically, North America is predicted to hold a significant market share of the global CRISPR market attributing to a thriving pharmaceutical and biotechnology industry, broad technology use, the growing frequency of lifestyle illnesses, rising healthcare costs, and increased R&D activities. The expanding biotechnology and pharmaceutical industries have also contributed to this rise. The CRISPR market in the area is seeing significant demand owing to the enormous applications in human stem cells and genetic engineering, as well as the expanding need for genetically modified organisms.

CRISPR Market Scope:

Report Metric Details
 Market size value in 2019  US$0.979 billion
 Market size value in 2026  US$8.406 billion
 Growth Rate  CAGR of 35.96% from 2019 to 2026
 Base year  2019
 Forecast period  2021–2026
 Forecast Unit (Value)  USD Billion
 Segments covered  Products, Application, And Geography
 Regions covered  North America, South America, Europe, Middle East and Africa, Asia Pacific
 Companies covered  Addgene, CRISPR Therapeutics, Editas Medicine, Egenesis, Inc., GE Healthcare,   GenScript Biotech Corporation, Horizon Discovery Group PLC, Integrated DNA   Technologies, Inc., Intellia Therapeutics, Inc., Lonza Group
 Customization scope  Free report customization with purchase

 

Segmentation:

  • By Products
    • Design Tools
    • Plasmid and Vector
    • Cas9 and g-RNA
    • Delivery System Products
  • By Applications
    • Genome Editing
    • Genetic Engineering
    • GMO and Crops
    • Human Stem Cells
    • Others
  • By Geography
    • North America
      • USA
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • UK
      • Germany
      • France
      • Spain
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • UAE
      • Israel
      • Others
    • Asia Pacific
      • Japan
      • China
      • India
      • South Korea
      • Taiwan
      • Thailand
      • Indonesia
      • Others

Frequently Asked Questions (FAQs)

Q1. What are the growth prospects for the CRISPR market?
A1. The global CRISPR market is estimated to grow at a CAGR of 35.96% over the forecast period.


Q2. What will be the CRISPR market size by 2026?
A2. The CRISPR market is estimated to reach a total market size of US$8.406 billion by 2026.


Q3. What is the size of the global CRISPR market?
A3. CRISPR Market was valued at US$0.979 billion in 2019. 


Q4. Which region holds the maximum market share of the CRISPR market?
A4. Geographically, North America is predicted to hold a significant market share of the global CRISPR market.


Q5. What factors are anticipated to drive the CRISPR market growth?
A5. The growing need for drug research, the risk of congenital abnormalities, and late pregnancies resulting in birth problems are key factors driving the CRISPR market forward.

1. Introduction
1.1. Market Definition
1.2. Market Segmentation


2. Research Methodology
2.1. Research Data
2.2. Assumptions


3. Executive Summary
3.1. Research Highlights


4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. The threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis


5. Global CRISPR Market Analysis, By Products
5.1. Introduction
5.2.  Design Tools
5.3. Plasmid and Vector
5.4. Cas9 and g-RNA
5.5. Delivery System Products


6. Global CRISPR Market Analysis, By Application
6.1. Introduction
6.2. Genome Editing
6.3. Genetic Engineering
6.4. GMO and Crops
6.5. Human Stem Cells
6.6. Others


7. Global CRISPR Market Analysis, By Geography
7.1. North America
7.1.1. USA
7.1.2. Canadá
7.1.3. Mexico
7.2. South America
7.2.1. Brazil
7.2.2. Argentina
7.2.3. Others
7.3. Europe
7.3.1. UK
7.3.2. Germany
7.3.3. France
7.3.4. Spain
7.3.5. Others
7.4. Middle East and Africa
7.4.1. Saudi Arabia
7.4.2. Israel
7.4.3. Others
7.5. Asia Pacific
7.5.1. Japan
7.5.2. China
7.5.3. India
7.5.4. Indonesia
7.5.5. Taiwan
7.5.6. Thailand
7.5.7. Others


8. Competitive Intelligence
8.1. Competitive Benchmarking and Analysis
8.2. Recent Investment and Deals
8.3. Strategies of Key Players


9. Company Profiles
9.1. Addgene
9.2. CRISPR Therapeutics
9.3. Editas Medicine
9.4. Egenesis, Inc.
9.5. GE Healthcare
9.6. GenScript Biotech Corporation
9.7. Horizon Discovery Group PLC
9.8. Integrated DNA Technologies, Inc.
9.9. Intellia Therapeutics, Inc.
9.10. Lonza Group

Addgene

CRISPR Therapeutics

Editas Medicine

Egenesis, Inc.

GE Healthcare

GenScript Biotech Corporation

Horizon Discovery Group PLC

Integrated DNA Technologies, Inc.

Intellia Therapeutics, Inc.

Lonza Group

 

Pricing

Explore Custom Options available with this study:

  •  Request customization
  •  Buy sections of the study
  •  Buy country specific report
  •  Request excel, Historical data
  •  Subscription inquiry
  •  Request special pricing

Our Value Proposition

Analyst Support

All our studies come with 2 months of analyst support.


Confidentiality

We are in compliance with the global privacy laws.

Connect With Us